SCILEX HOLDING COMPANY - COMMON STOCK

Scilex Pharmaceuticals Inc, a Wholly Owned Subsidiary of Scilex Holding Company, Announces Successful End of Phase II Meeting with FDA Leading to an Agreed Path Forward to NDA Upon Completion of Phase III Trials for Blockbuster Product Candidate, SP-103 (Lidocaine Topical System) 5.4%, a Next-Generation, Triple-Strength Formulation of ZTlido, for the Treatment of Chronic Neck Pain Associated with Muscle Spasms

30 Oct 2024 06:00:00 By Nasdaq GlobeNewswire

Scilex Holding Company, Following its Prior Announcement of the Record Date for a Dividend of Preferred Stock, Reiterates Information Previously Provided to Scilex Stockholders Regarding Manipulative and Naked Short Selling of Scilex Common Stock

29 Oct 2024 06:00:00 By Nasdaq GlobeNewswire

Scilex Holding Company sets November 7, 2024 as the Record Date for a Dividend of Preferred Stock Exchangeable for up to 10% of Scilex’s Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary

28 Oct 2024 06:00:00 By Nasdaq GlobeNewswire

Scilex Holding Company Announces that its Board of Directors has Authorized Management to Explore Ways to Maximize the Value of its Wholly Owned Subsidiary, Scilex Pharmaceuticals Inc., including by way of conducting a spinoff or public listing of securities of Scilex Pharmaceuticals Inc. Scilex Pharmaceuticals Commercial Products Include Three Non-Opioid Approved Products and Pipeline of Phase 3 Ready SP-103 With Greater Than a $1.0 Billion Revenue Potential

16 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, Provides Timing to File in October 2024 a Registration Statement on Form S-4 with the SEC relating to the Previously Announced Proposed Business Combination Between Semnur and Denali with a Pre-Transaction Equity Value of $2.5 Billion

16 Oct 2024 04:00:00 By Nasdaq GlobeNewswire

Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results for the Quarter Ended September 30, 2024

08 Oct 2024 13:58:34 By Nasdaq GlobeNewswire

Scilex Holding Company Announces Closing of a $50 Million Registered Convertible Financing

08 Oct 2024 11:50:47 By Nasdaq GlobeNewswire

Scilex Holding Company Announces Signing of a $50 Million Registered Convertible Financing to Refinance and Restructure Existing Debt & Further Strengthens Financial Profile

07 Oct 2024 09:52:36 By Nasdaq GlobeNewswire

Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Dividend Stock Previously Distributed by Sorrento to its Stockholders as a Dividend to January 31, 2025

26 Sep 2024 09:00:00 By Nasdaq GlobeNewswire

Scilex Holding Company Announces the Continuing Support from Endeavor Distribution LLC in the Multi-Year Agreement for Scilex’s Commercial Products and the Satisfaction of FSF 33433 LLC $10 Million Loan

18 Sep 2024 09:00:00 By Nasdaq GlobeNewswire

Scilex Holding Company Announces It Has Received the Drug Distributor Accreditation from the National Association of Boards of Pharmacy® (NABP®)

12 Sep 2024 09:00:00 By Nasdaq GlobeNewswire

Scilex Holding Company to Present at the 26th Annual H.C. Wainwright Global Investment Conference

09 Sep 2024 09:00:00 By Nasdaq GlobeNewswire

Scilex Holding Company Announces Acceptance of Presentation at the 2024 American College of Rheumatology Convergence Conference to be held at the Walter E. Washington Convention Center in Washington, D.C. on November 14 – 19, 2024

05 Sep 2024 09:00:00 By Nasdaq GlobeNewswire

Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. (Nasdaq: DECA) Announce Signing of a Merger Agreement for a proposed Business Combination, Providing for a Pre-Transaction Equity Value of Semnur of $2.5 Billion

03 Sep 2024 09:00:00 By Nasdaq GlobeNewswire

Scilex Holding Company to Present Oral, Poster Presentations and Symposia on ZTlido (lidocaine topical system) at the 2024 Annual PAINWeek Conference in Las Vegas, NV on September 3-5, 2024

30 Aug 2024 09:00:00 By Nasdaq GlobeNewswire

Scilex Holding Company Announces FDA Final Approval to Precision Dosing for GLOPERBA® Label

29 Aug 2024 09:00:00 By Nasdaq GlobeNewswire

Scilex Holding Company Announces the U.S. Patent and Trademark Office Will Be Issuing New ELYXYB® Patent Related to the Treatment of Acute Pain

21 Aug 2024 09:00:00 By Nasdaq GlobeNewswire

Scilex Holding Company Enters into Master Distributor Agreement Among CH Trading Group and Devart Middle East for the Distribution of ZTlido® in Morocco, Tunisia, Libya, Jordan, Iraq, and South Africa

09 Aug 2024 09:00:00 By Nasdaq GlobeNewswire

Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results for the Month Ended July 31, 2024

01 Aug 2024 09:00:00 By Nasdaq GlobeNewswire

Scilex Holding Company Announces Publication of Its Inaugural Sustainability Report

24 Jul 2024 10:52:55 By Nasdaq GlobeNewswire